<?xml version="1.0" encoding="UTF-8"?>
<ref id="B30">
 <label>30</label>
 <mixed-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Bielekova</surname>
    <given-names>B</given-names>
   </name>
   <name>
    <surname>Catalfamo</surname>
    <given-names>M</given-names>
   </name>
   <name>
    <surname>Reichert-Scrivner</surname>
    <given-names>S</given-names>
   </name>
   <name>
    <surname>Packer</surname>
    <given-names>A</given-names>
   </name>
   <name>
    <surname>Cerna</surname>
    <given-names>M</given-names>
   </name>
   <name>
    <surname>Waldmann</surname>
    <given-names>TA</given-names>
   </name>
   <etal/>
  </person-group>
  <article-title>Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis</article-title>. 
  <source>Proc Natl Acad Sci U S A</source> (
  <year>2006</year>) 
  <volume>103</volume>:
  <fpage>5941</fpage>â€“
  <lpage>6</lpage>.
  <pub-id pub-id-type="doi">10.1073/pnas.0601335103</pub-id>
  <?supplied-pmid 16585503?>
  <pub-id pub-id-type="pmid">16585503</pub-id>
 </mixed-citation>
</ref>
